Literature DB >> 28911059

Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy.

F Bozzetti1.   

Abstract

Sarcopenia has recently emerged as a new condition that, independently from malnutrition, may adversely affect the prognosis of cancer patients. Purpose of this narrative review is to define the prevalence of sarcopenia in different primaries, its role in leading to chemotherapy toxicity and decreased compliance with the oncological therapy and the effect of some drugs on the onset of sarcopenia. Finally, the review aims to describe the current approaches to restore the muscle mass through nutrition, exercise and anti-inflammatory agents or multimodal programmes with a special emphasis on the results of randomized controlled trials. The examination of the computed tomography scan at the level of the third lumbar vertebra-a common procedure for staging many tumours-has allowed the oncologist to evaluate the muscle mass and to collect many retrospective data on the prevalence of sarcopenia and its clinical consequences. Sarcopenia is a condition affecting a high percentage of patients with a range depending on type of primary tumour and stage of disease. It is noteworthy that patients may be sarcopenic even if their nutritional status is apparently maintained or they are obese. Sarcopenic patients exhibited higher chemotherapy toxicity and poorer compliance with oncological treatments. Furthermore, several antineoplastic drugs appeared to worsen the sarcopenic status. Therapeutic approaches are several and this review will focus on those validated by randomized controlled trials. They include the use of ω-3-enriched oral nutritional supplements and orexigenic agents, the administration of adequate high-protein regimens delivered enterally or parenterally, and programmes of physical exercise. Better results are expected combining different procedures in a multimodal approach. In conclusion, there are several premises to prevent/treat sarcopenia. The oncologist should coordinate this multimodal approach by selecting priorities and sequences of treatments and then involving a nutrition health care professional or a physical therapist depending on the condition of the single patient.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cancer and sarcopenia; sarcopenia; sarcopenia and chemotherapy; sarcopenia and prognosis; sarcopenia and toxicity; sarcopenia therapy

Mesh:

Substances:

Year:  2017        PMID: 28911059     DOI: 10.1093/annonc/mdx271

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  56 in total

Review 1.  Chemotherapy-Induced Sarcopenia.

Authors:  Federico Bozzetti
Journal:  Curr Treat Options Oncol       Date:  2020-01-30

2.  Clinical and economic value of oral nutrition supplements in patients with cancer: a position paper from the Survivorship Care and Nutritional Support Working Group of Alliance Against Cancer.

Authors:  Riccardo Caccialanza; Alessandro Laviano; Cristina Bosetti; Mariateresa Nardi; Valentina Casalone; Lucilla Titta; Roberto Mele; Giovanni De Pergola; Francesco De Lorenzo; Paolo Pedrazzoli
Journal:  Support Care Cancer       Date:  2022-07-06       Impact factor: 3.603

3.  CT evaluated sarcopenia signals: Shorter survival for small cell lung cancer patients.

Authors:  A Pekařová; M Pekař; D Daniš; Z Nováková
Journal:  Physiol Res       Date:  2021-12-31       Impact factor: 1.881

4.  Nutritional status assessed by Patient-Generated Subjective Global Assessment is associated with toxicity to chemoradiotherapy in women with cervical cancer: a prospective study.

Authors:  Amanda Pereira Mota; Mariah Azevedo Aredes; Juliana De Oliveira Miguel; Gabriela Villaça Chaves
Journal:  Eur J Clin Nutr       Date:  2022-07-19       Impact factor: 4.884

5.  Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.

Authors:  Tim A Labeur; Jeroen L A van Vugt; David W G Ten Cate; R Bart Takkenberg; Jan N M IJzermans; Bas Groot Koerkamp; Robert A de Man; Otto M van Delden; Ferry A L M Eskens; Heinz-Josef Klümpen
Journal:  Liver Cancer       Date:  2018-11-02       Impact factor: 11.740

Review 6.  Symptoms During Outpatient Cancer Treatment and Options for Their Management

Authors:  Mitra Tewes; Freerk Baumann; Martin Teufel; Christoph Ostgathe
Journal:  Dtsch Arztebl Int       Date:  2021-04-30       Impact factor: 5.594

7.  Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting.

Authors:  Calvin L Cole; John F Bachman; Jian Ye; Joseph Murphy; Scott A Gerber; Christopher A Beck; Brendan F Boyce; Gowrishankar Muthukrishnan; Joe V Chakkalakal; Edward M Schwarz; David Linehan
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-05-07       Impact factor: 12.910

Review 8.  The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer.

Authors:  Rishi Jain; Chris Coss; Peter Whooley; Mitch Phelps; Dwight H Owen
Journal:  Curr Oncol Rep       Date:  2020-05-15       Impact factor: 5.075

9.  The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy.

Authors:  Tsuyoshi Takeda; Takashi Sasaki; Chisaki Suzumori; Takafumi Mie; Takaaki Furukawa; Yuto Yamada; Akiyoshi Kasuga; Masato Matsuyama; Masato Ozaka; Naoki Sasahira
Journal:  Int J Clin Oncol       Date:  2021-03-31       Impact factor: 3.850

10.  Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants.

Authors:  Rishi Jain; Elizabeth Handorf; Vipin Khare; Matthew Blau; Yana Chertock; Michael J Hall
Journal:  Oncologist       Date:  2019-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.